Uncategorized

Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout

Published

on

The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with Takeda and Eisai.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version